drug eruptions/tyrosine

Nuoroda įrašoma į mainų sritį

StraipsniaiKlinikiniai tyrimaiPatentai

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 16 rezultatus

Purpuric drug eruptions induced by EGFR tyrosine kinase inhibitors are associated with IQGAP1-mediated increase in vascular permeability.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used as a treatment for non-small cell lung cancer. There have been some reports of EGFR-TKIs being associated with vascular adverse events. We found that EGFR-TKIs decreased the proliferation of HMEC-1 (immortalized human

Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

UNASSIGNED Purpuric skin lesions have only rarely been reported in patients receiving epidermal growth factor receptor inhibitors. However, their clinical and histopathologic presentations have varied considerably. UNASSIGNED To characterize purpuric skin eruptions caused by epidermal growth factor

Immunohistochemical characterization of cutaneous drug eruptions by STI571.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND STI571, a selective BCR-ABL tyrosine kinase inhibitor, is a promising new drug for chronic myelogenous leukemia (CML). However, the drug has been reported to be associated with adverse cutaneous drug eruptions with high frequency. OBJECTIVE In this study, the characteristics of the

Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Imatinib mesylate, the first agent approved for the treatment of unresectable or metastatic gastrointestinal stromal tumor, is a tyrosine kinase inhibitor targeting (KIT) and the platelet-derived growth factor receptor-α and -β. However, imatinib administration can be accompanied by various adverse

Imatinib mesylate-induced lichenoid drug eruption.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists

Fixed drug eruption related to sunitinib: a case report.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor. It has been approved for the treatment of gastro-intestinal stromal tumor and advanced renal cell carcinoma. Fixed drug eruption related to sunitinib is a rare cutaneous adverse drug reaction.

Cutaneous drug eruptions induced by sorafenib: a case series.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Sorafenib, an epidermal growth factor receptor inhibitor, is a novel treatment used for malignancies resistant to traditional chemotherapy. Epidermal growth factor receptors (EGFR) are a family of 4 transmembrane tyrosine kinase receptors that, via signal transduction pathways, mediate cell growth,

Ponatinib-induced ichthyosiform drug eruption: insights into acquired ichthyosis.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Cutaneous adverse events are commonly experienced with use of tyrosine kinase inhibitors in the treatment of leukemia and typically include nonspecific cutaneous eruptions and xerosis. We report the case of a man who experienced an ichthyosiform drug eruption while taking ponatinib, a

Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Vandetanib is an inhibitor of the vascular endothelial growth factor receptor 2 tyrosine kinase and the epidermal growth factor receptor tyrosine kinase, recently used in the treatment of different tumors. We describe a case of a photo-allergic reaction to vandetanib in an 80-year-old Caucasian

Purpuric drug eruption and alopecia induced by erlotinib.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

We herein report a case of diffuse alopecia with pustules on the scalp and purpuric lesions on the lower legs in a Japanese man after treatment with erlotinib. This is a unique case in which rare skin eruptions simultaneously occurred. We discuss herein a combination of skin eruptions as an adverse

Vandetanib-induced Phototoxic Drug Eruption Treated with Polypodium Leucotomos Extract: A Case Report and Review of the Literature.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Vandetanib is a tyrosine kinase inhibitor approved by the United States Food and Drug Administration for the treatment of metastatic medullary thyroid cancer. It has been linked to a variety of dermatologic reactions, including photosensitivity. We describe the case of a 55-year-old man who

[Peritoneal dissemination from gastrointestinal stromal tumor of small intestine responding completely to imatinib mesylate (STI 571)].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The prognosis of metastatic or recurrent GISTs is poor, because these tumors resist chemotherapy and radiotherapy. We report a patient with recurrent GIST who underwent molecularly targeted therapy with imatinib, a novel oral tyrosine kinase inhibitor. A 64-year-old man presented with large

Mycosis fungoides-like reaction in a patient treated with Gleevec.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Gleevec trade mark is a protein tyrosine kinase inhibitor used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumor. Currently, Gleevec is also being used in protocols for treatment of other malignancies such as melanoma. A few, non-descript cutaneous

Demodex folliculitis mimicking acute graft-vs-host disease.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE Acute graft-vs-host disease (GVHD) typically requires high-dose systemic steroids as first-line treatment. Like drug eruptions, viral exanthema, and toxic erythema of chemotherapy, Demodex folliculitis is a clinical mimicker of acute GVHD and requires nonimmunosuppressive therapy. This

Crizotinib-associated erythema multiforme in a lung cancer patient.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Crizotinib is an oral small-molecule anaplastic lymphoma kinase (ALK) tyrosine-kinase inhibitor for the treatment of ALK-positive non-small-cell lung cancer (NSCLC). A 63-year old woman with postoperative relapsed ALK-positive NSCLC was treated with crizotinib. Erythema multiforme (EM) occurred one

Ankstesnis
1
2
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais